Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 400

1.

A virus-like particle vaccine prevents equine encephalitis virus infection in nonhuman primates.

Ko SY, Akahata W, Yang ES, Kong WP, Burke CW, Honnold SP, Nichols DK, Huang YS, Schieber GL, Carlton K, DaSilva L, Traina-Dorge V, Vanlandingham DL, Tsybovsky Y, Stephens T, Baxa U, Higgs S, Roy CJ, Glass PJ, Mascola JR, Nabel GJ, Rao SS.

Sci Transl Med. 2019 May 15;11(492). pii: eaav3113. doi: 10.1126/scitranslmed.aav3113.

PMID:
31092692
2.

Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells.

Bu W, Joyce MG, Nguyen H, Banh DV, Aguilar F, Tariq Z, Yap ML, Tsujimura Y, Gillespie RA, Tsybovsky Y, Andrews SF, Narpala SR, McDermott AB, Rossmann MG, Yasutomi Y, Nabel GJ, Kanekiyo M, Cohen JI.

Immunity. 2019 May 21;50(5):1305-1316.e6. doi: 10.1016/j.immuni.2019.03.010. Epub 2019 Apr 9.

PMID:
30979688
3.

All for one and one for all to fight flu.

Nabel GJ, Shiver JW.

Nature. 2019 Jan;565(7737):29-31. doi: 10.1038/d41586-018-07654-w. No abstract available.

PMID:
30573785
4.

Development of a Pan-H1 Influenza Vaccine.

Darricarrère N, Pougatcheva S, Duan X, Rudicell RS, Chou TH, DiNapoli J, Ross TM, Alefantis T, Vogel TU, Kleanthous H, Wei CJ, Nabel GJ.

J Virol. 2018 Oct 29;92(22). pii: e01349-18. doi: 10.1128/JVI.01349-18. Print 2018 Nov 15.

5.

Systemic immune-checkpoint blockade with anti-PD1 antibodies does not alter cerebral amyloid-β burden in several amyloid transgenic mouse models.

Latta-Mahieu M, Elmer B, Bretteville A, Wang Y, Lopez-Grancha M, Goniot P, Moindrot N, Ferrari P, Blanc V, Schussler N, Brault E, Roudières V, Blanchard V, Yang ZY, Barneoud P, Bertrand P, Roucourt B, Carmans S, Bottelbergs A, Mertens L, Wintmolders C, Larsen P, Hersley C, McGathey T, Racke MM, Liu L, Lu J, O'Neill MJ, Riddell DR, Ebneth A, Nabel GJ, Pradier L.

Glia. 2018 Mar;66(3):492-504. doi: 10.1002/glia.23260. Epub 2017 Nov 14.

PMID:
29134678
6.

Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques.

Xu L, Pegu A, Rao E, Doria-Rose N, Beninga J, McKee K, Lord DM, Wei RR, Deng G, Louder M, Schmidt SD, Mankoff Z, Wu L, Asokan M, Beil C, Lange C, Leuschner WD, Kruip J, Sendak R, Kwon YD, Zhou T, Chen X, Bailer RT, Wang K, Choe M, Tartaglia LJ, Barouch DH, O'Dell S, Todd JP, Burton DR, Roederer M, Connors M, Koup RA, Kwong PD, Yang ZY, Mascola JR, Nabel GJ.

Science. 2017 Oct 6;358(6359):85-90. doi: 10.1126/science.aan8630. Epub 2017 Sep 20.

7.

Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates.

Saunders KO, Nicely NI, Wiehe K, Bonsignori M, Meyerhoff RR, Parks R, Walkowicz WE, Aussedat B, Wu NR, Cai F, Vohra Y, Park PK, Eaton A, Go EP, Sutherland LL, Scearce RM, Barouch DH, Zhang R, Von Holle T, Overman RG, Anasti K, Sanders RW, Moody MA, Kepler TB, Korber B, Desaire H, Santra S, Letvin NL, Nabel GJ, Montefiori DC, Tomaras GD, Liao HX, Alam SM, Danishefsky SJ, Haynes BF.

Cell Rep. 2017 Feb 28;18(9):2175-2188. doi: 10.1016/j.celrep.2017.02.003.

8.

Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012).

Crank MC, Wilson EM, Novik L, Enama ME, Hendel CS, Gu W, Nason MC, Bailer RT, Nabel GJ, McDermott AB, Mascola JR, Koup RA, Ledgerwood JE, Graham BS; VRC012 Study Team.

PLoS One. 2016 Nov 15;11(11):e0166393. doi: 10.1371/journal.pone.0166393. eCollection 2016.

9.

Reconstituted B cell receptor signaling reveals carbohydrate-dependent mode of activation.

Villar RF, Patel J, Weaver GC, Kanekiyo M, Wheatley AK, Yassine HM, Costello CE, Chandler KB, McTamney PM, Nabel GJ, McDermott AB, Mascola JR, Carr SA, Lingwood D.

Sci Rep. 2016 Oct 31;6:36298. doi: 10.1038/srep36298.

10.

Report of the Cent Gardes HIV Vaccines Conference, Part 2: The cellular immune response. Fondation Mérieux Conference Center, Veyrier-du-Lac, France, 25-27 October 2015.

Girard MP, Le-Grand R, Picot V, Longuet C, Nabel GJ.

Vaccine. 2016 Nov 4;34(46):5470-5473. doi: 10.1016/j.vaccine.2016.09.034. Epub 2016 Sep 28. No abstract available.

PMID:
27692524
11.

Report of the Cent Gardes HIV Vaccines Conference. Part 1: The antibody response; Fondation Mérieux Conference Center, Veyrier-du-Lac, France, 25-27 October 2015.

Girard MP, Le-Grand R, Picot V, Longuet C, Nabel GJ.

Vaccine. 2016 Jun 30;34(31):3557-61. doi: 10.1016/j.vaccine.2016.05.024. Epub 2016 May 20.

PMID:
27216761
12.

Once and future epidemics: Zika virus emerging.

Nabel GJ, Zerhouni EA.

Sci Transl Med. 2016 Mar 16;8(330):330ed2. doi: 10.1126/scitranslmed.aaf4548. Epub 2016 Mar 16. No abstract available.

PMID:
27089202
13.

In vitro reconstitution of B cell receptor-antigen interactions to evaluate potential vaccine candidates.

Weaver GC, Villar RF, Kanekiyo M, Nabel GJ, Mascola JR, Lingwood D.

Nat Protoc. 2016 Feb;11(2):193-213. doi: 10.1038/nprot.2016.009. Epub 2016 Jan 7.

PMID:
26741406
14.

Combination recombinant simian or chimpanzee adenoviral vectors for vaccine development.

Cheng C, Wang L, Ko SY, Kong WP, Schmidt SD, Gall JGD, Colloca S, Seder RA, Mascola JR, Nabel GJ.

Vaccine. 2015 Dec 16;33(51):7344-7351. doi: 10.1016/j.vaccine.2015.10.023. Epub 2015 Oct 26.

PMID:
26514419
15.

Activation and lysis of human CD4 cells latently infected with HIV-1.

Pegu A, Asokan M, Wu L, Wang K, Hataye J, Casazza JP, Guo X, Shi W, Georgiev I, Zhou T, Chen X, O'Dell S, Todd JP, Kwong PD, Rao SS, Yang ZY, Koup RA, Mascola JR, Nabel GJ.

Nat Commun. 2015 Oct 20;6:8447. doi: 10.1038/ncomms9447.

16.

Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization.

Asokan M, Rudicell RS, Louder M, McKee K, O'Dell S, Stewart-Jones G, Wang K, Xu L, Chen X, Choe M, Chuang G, Georgiev IS, Joyce MG, Kirys T, Ko S, Pegu A, Shi W, Todd JP, Yang Z, Bailer RT, Rao S, Kwong PD, Nabel GJ, Mascola JR.

J Virol. 2015 Dec;89(24):12501-12. doi: 10.1128/JVI.02097-15. Epub 2015 Oct 7.

17.

Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection.

Yassine HM, Boyington JC, McTamney PM, Wei CJ, Kanekiyo M, Kong WP, Gallagher JR, Wang L, Zhang Y, Joyce MG, Lingwood D, Moin SM, Andersen H, Okuno Y, Rao SS, Harris AK, Kwong PD, Mascola JR, Nabel GJ, Graham BS.

Nat Med. 2015 Sep;21(9):1065-70. doi: 10.1038/nm.3927. Epub 2015 Aug 24.

PMID:
26301691
18.

Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site.

Kanekiyo M, Bu W, Joyce MG, Meng G, Whittle JR, Baxa U, Yamamoto T, Narpala S, Todd JP, Rao SS, McDermott AB, Koup RA, Rossmann MG, Mascola JR, Graham BS, Cohen JI, Nabel GJ.

Cell. 2015 Aug 27;162(5):1090-100. doi: 10.1016/j.cell.2015.07.043. Epub 2015 Aug 13.

19.

HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies.

Williams WB, Liao HX, Moody MA, Kepler TB, Alam SM, Gao F, Wiehe K, Trama AM, Jones K, Zhang R, Song H, Marshall DJ, Whitesides JF, Sawatzki K, Hua A, Liu P, Tay MZ, Seaton KE, Shen X, Foulger A, Lloyd KE, Parks R, Pollara J, Ferrari G, Yu JS, Vandergrift N, Montefiori DC, Sobieszczyk ME, Hammer S, Karuna S, Gilbert P, Grove D, Grunenberg N, McElrath MJ, Mascola JR, Koup RA, Corey L, Nabel GJ, Morgan C, Churchyard G, Maenza J, Keefer M, Graham BS, Baden LR, Tomaras GD, Haynes BF.

Science. 2015 Aug 14;349(6249):aab1253. doi: 10.1126/science.aab1253. Epub 2015 Jul 30.

20.

Supplemental Content

Loading ...
Support Center